Scholarlink

<p>Accurate pre-operative discrimination between ovarian endometriomas (EMs) and other benign ovarian tumors is crucial for surgical planning and fertility counseling. This study aimed to evaluate the diagnostic performance of serum CA125, CA19-9, and HE4 in differentiating endometriomas from non-endometriotic benign ovarian cysts. This retrospective cohort study included 654 patients with histologically confirmed benign ovarian cysts (343 endometriomas and 311 other benign ovarian tumors) from January 2024 to March 2025. Serum CA125, CA19-9, and HE4 levels were compared between groups. Receiver operating characteristic (ROC) analysis was performed to assess diagnostic accuracy, with stratified analyses by age, dysmenorrhea, cyst laterality, and parity. Patients with endometriomas had significantly elevated CA125 (median: 56.40 vs. 17.30 U/mL, P&lt;0.001) and HE4 (31.50 vs. 14.94 pmol/L, P&lt;0.001), whereas CA19-9 showed no significant difference. ROC analysis revealed that CA125 had excellent diagnostic performance (AUC=0.895; sensitivity=85.7% (95% CI: 81.6-89.2%); specificity=80.6% (95% CI: 75.8-84.9%) at cutoff=27.45 U/mL), consistently superior across all subgroups. HE4 demonstrated moderate utility (AUC=0.683), while CA19-9 lacked discriminatory value. Serum CA125 reliably distinguishes endometriomas from other benign ovarian tumors across diverse clinical scenarios. CA125 should be routinely integrated as a biochemical adjunct to ultrasonography, whereas HE4 and CA19-9 have limited clinical utility in this context. The retrospective design of this study should be considered when interpreting the findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CA125 Outperforms HE4 and CA19-9 as a Serum Biomarker for Preoperative Diagnosis of Ovarian Endometriomas: A Retrospective Cohort Study

  • 期刊论文

  • 发表日期：

    2026年5月11日

查看全文
  • Huanli He,
  • Xiaohui Yang,
  • Yifen Li,
  • Yu Zhang,
  • Qingjian Ye

摘要

Accurate pre-operative discrimination between ovarian endometriomas (EMs) and other benign ovarian tumors is crucial for surgical planning and fertility counseling. This study aimed to evaluate the diagnostic performance of serum CA125, CA19-9, and HE4 in differentiating endometriomas from non-endometriotic benign ovarian cysts. This retrospective cohort study included 654 patients with histologically confirmed benign ovarian cysts (343 endometriomas and 311 other benign ovarian tumors) from January 2024 to March 2025. Serum CA125, CA19-9, and HE4 levels were compared between groups. Receiver operating characteristic (ROC) analysis was performed to assess diagnostic accuracy, with stratified analyses by age, dysmenorrhea, cyst laterality, and parity. Patients with endometriomas had significantly elevated CA125 (median: 56.40 vs. 17.30 U/mL, P<0.001) and HE4 (31.50 vs. 14.94 pmol/L, P<0.001), whereas CA19-9 showed no significant difference. ROC analysis revealed that CA125 had excellent diagnostic performance (AUC=0.895; sensitivity=85.7% (95% CI: 81.6-89.2%); specificity=80.6% (95% CI: 75.8-84.9%) at cutoff=27.45 U/mL), consistently superior across all subgroups. HE4 demonstrated moderate utility (AUC=0.683), while CA19-9 lacked discriminatory value. Serum CA125 reliably distinguishes endometriomas from other benign ovarian tumors across diverse clinical scenarios. CA125 should be routinely integrated as a biochemical adjunct to ultrasonography, whereas HE4 and CA19-9 have limited clinical utility in this context. The retrospective design of this study should be considered when interpreting the findings.